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Abstract 15 
The Prestwick library was screened for antibacterial activity or ‘antibiotic-resistance breaking’ (ARB) 16 
potential against four species of Gram-negative pathogens. Discounting known antibacterials, the 17 
screen identified very few ARB hits, which were strain/drug specific. These ARB hits included 18 
antimetabolites (zidovudine, floxuridine, didanosine, gemcitabine), anthracyclines (daunorubicin, 19 
mitoxantrone, epirubicin) and psychoactive drugs (gabapentin, fluspirilene, oxethazaine). This 20 
suggests that there are few approved drugs which could be directly repositioned as adjunct-21 
antibacterials and these will need robust testing to validate efficacy.  22 
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The need for new antibiotics is driven by the rapid spread of multidrug resistant (MDR) bacterial 24 
pathogens and the absence of new antibiotics in the clinical development pathway is significant 25 
cause for concern. The idea of repurposing existing drugs, which are currently used as treatments for 26 
other disease areas is attractive because, due to the known safety profile of approved drugs, the 27 
cost and time to clinic could be significantly lower than novel scaffolds 1. Examples of successful 28 
repurposing screens, outside of the antibacterial area, have produced candidates for Ebola, Zika 29 
virus and anti-cancer therapies 2-4. Recent studies for the identification of new antibacterial leads 30 
have focussed on two key areas; i) identification of direct antibacterial hits for one or more target 31 
bacteria 5, 6, and ii) screening for compounds which synergise with existing antibiotics, thereby 32 
restoring activity of the antibiotic against strains/species which are currently resistant to their use 7. 33 
Several previous studies identified antibacterial activities that are too weak to be effective on their 34 
own and would require exposures greater than the maximum concentration achievable with their 35 
primary pharmacology and recommended safe dosing 7, possibly because of the bacterial membrane 36 
barriers.  37 
 38 
The current study aimed to identify either direct-acting antibiotics, or compounds which sensitise 39 
resistant Gram-negative strains to one or more antibiotics, looking to identify ‘Antibiotic Resistance 40 
Breakers’ (ARBs).  41 
A high-throughput combination screen (HTCS) of potential ARBs and antibiotics was performed in 42 
384-well format from the Prestwick library of 1280 selected compounds in combination with five 43 
antibiotics or 0.1 % DMSO, in duplicate. Each replicate was from independent dilution plates by 44 
using independent inocula on two different days. The potential ARBs were tested at two 45 
concentrations, 20 µM and 7 µM, in combination with antibiotics at 0.125 x MIC. Concentrations 46 
were selected to balance the probability of achieving a significant number of hits with realistic 47 
concentrations which align with the likely Cmax for a typical drug.  Where the MIC was >128 mg/L, 48 
the antibiotic was tested at 16 mg/L. The MICs of test articles were determined in cation-adjusted 49 
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Mueller-Hinton broth (caMHB; Oxoid), using the Clinical and Laboratory Standards Institute (CLSI) 50 
guidelines M7-A10 & M100-S26.  51 
Clinical isolates of Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae and 52 
Acinetobacter baumannii which were recently highlighted by the World Health Organisation as 53 
priority pathogens for which new antibiotics are urgently required 8, were selected which were 54 
resistant to each antibiotic. In some species (K. pneumoniae and A. baumannii), this involved use of 55 
two strains to cover all resistance profiles, and some resistance profiles were not available (Table 56 
S1).  57 
During the HTCS, bacterial growth was determined by reading on a modal reader (Infinite 500, 58 
Tecan) at 600 nm after 24 h of incubation. For each plate, OD600 measurement was done at 2 59 
timepoints, T0 h (to determine the background signal related to the coloured compounds) and T24 h 60 
at the end of incubation. After blank substitution, calculated by subtracting OD600 at T0 h from 61 
OD600 at T24 h, a normalization step was carried out between OD600 values obtained in wells 62 
containing the compounds compared to those obtained in control wells (DMSO wells – maximal 63 
growth). Data analysis for each run was performed with Genedata Screener software. The workflow 64 
from the raw data associated to plate-map up to the normalization step was fully automated 65 
allowing for complete tracking of all data.  The Z’ factor and assay window were determined for each 66 
plate, between the positive control in presence of antibiotic at 0.125 x MIC and the negative control 67 
9. The Z’ factor for each combination of strain and antibiotic was between 0.5 – 0.8, plates displaying 68 
a Z’ factor < 0.5 were automatically retested.  69 
After statistical analysis, hits were defined as data points with an activity > hit threshold based on 70 
the Sigma method (mean + 3 standard deviations), unless otherwise stated. Results were expressed 71 
as percentage of growth inhibition compared to that in untreated controls (exposed to 0.1% DMSO 72 
only), assessed by optical density.  73 
 o
n
 June 20, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
4 
 
Firstly, compounds from the library were tested for direct antimicrobial activity at two 74 
concentrations, 7 M and 20 M, in the presence of 0.1 % DMSO (Figure S1 and S2). The number of 75 
direct hits at either concentration varied considerably between species, with 29 for E. coli, 16 for P. 76 
aeruginosa, 85 for the two A. baumannii strains combined and 53 for the two K. pneumoniae strains 77 
(discounting overlapping hits between the two strains of the same species and between the two 78 
concentrations tested) (Table S2). As might be expected we saw three scenarios with respect to dose 79 
response, i) compounds which were equally effective at both concentrations, ii) compounds which 80 
were effective at 20 M which were not effective as either direct antibacterials or ARBs at 7 M and 81 
iii) compounds which were ARBs at 7 M but which were directly antibacterial at 20 M.  82 
Compounds at 7 M or 20 M were also tested in combination with antibiotics at concentrations of 83 
0.125 x MIC. There were few hits which overlapped between species (Figure 1). Most of the 84 
compounds which did overlap were known antimicrobials or antiseptics (Tables S5-S10). A number 85 
of compounds showed interesting potentiation, and these are discussed further below and in the 86 
supplementary file.    87 
Three anthracycline-related molecules, daunorubicin, mitoxantrone and epirubicin showed 88 
potentiation with one or more combination of drug and species (Table 1). The pattern of activity 89 
differed between the three molecules tested, with no evidence of direct antibacterial activity, but 90 
differing levels of potentiation for other antibiotics.  91 
Several nucleotide/nucleoside analogues, identified as antimetabolites and/or antiviral agents, also 92 
showed potentiation with one or more antibiotic (Table 1). Whilst simplistically such molecules 93 
might be expected to have similar effects, via interference with DNA/RNA metabolism in the cell, 94 
there were clear differences in the spectrum of activity between the compounds.  95 
Two psychoactive compounds, fluspirilene and oxethazaine were also found to act as ARBs with 96 
colistin and merited further investigation, given the possibility that their mode of action might be 97 
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different to cationic compounds identified previously as able to potentiate colistin (for example 98 
pentamidine 10, which was not found to potentiate colistin activity in this study, and cysteamine, 99 
which was not included in this study 11). The MIC of colistin alone, and in combination with set 100 
concentrations of fluspirilene and oxethazaine was determined as above, but in non-cation adjusted 101 
Mueller-Hinton broth (Oxoid) and polypropylene plates, incubated for 20 hours at 37°C 12.  102 
Colistin potentiation by fluspirilene and oxethazaine in a wider panel of colistin-resistant strains of K. 103 
pneumoniae and a smaller number of other Gram-negative pathogens was tested as examples of 104 
compounds which were clear ARBs with very little direct antimicrobial activity (Table S3). The studies 105 
were designed as a fixed concentration synergy experiment, looking for ARB activity. Initially, MICs 106 
and growth curves were used to analyse direct effects of the two compounds. In most cases the MIC 107 
was >160 μM for Klebsiella spp. and P. aeruginosa isolates. For E. coli, all strains had an MIC of 160 108 
μM or above for oxethazaine, but two strains (LEC001 and 319238/UR) had MICs of 80 μM for 109 
fluspirilene. The notable exception to the high MIC values identified, were the A. baumannii strains, 110 
which showed an MIC of 20 μM for both oxethazaine and fluspirilene in both colistin-resistant 111 
strains (Table S4).  112 
Despite being ARB hits with the original colistin-resistant K. pneumoniae strain used in the HTCS, 113 
within the broader panel of Klebsiella isolates, there were few examples of clear colistin potentiation 114 
with either compound. Only strains NCTC 13439 CST 2A (4-fold), MGH 78578 CST A (8-fold) and 115 
m109 CST 1B (32-fold) showed greater than 2-fold potentiation of colistin with fluspirilene (Figure 2, 116 
Table S3) and no strains showed this level of potentiation with oxethazaine.  117 
In contrast, fluspirilene showed potentiation of colistin in all of the other Gram-negative species 118 
tested, with levels ranging from 4-fold (A. baumannii W1 CST_R) to >128 fold (E. coli LEC001). The 119 
latter strain was also the only strain which showed potentiation with oxethazaine, again with 120 
increased susceptibility to colistin of >128 fold. Whether derivatives of fluspirilene merit further 121 
investigation as a stand-alone antibiotic or as an ARB, may depend on the novelty of its mechanism 122 
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of action. The developability is hampered by the relatively high concentration required to achieve 123 
potentiation of colistin, for example, around 20 µM against K. pneumoniae (equivalent to 9.5 mg/L) 124 
compared to the daily dose (10 mg i.m. per day).   125 
The current screen, in line with many other studies, suggests that there might be very few licensed 126 
drug compounds which could be simply repositioned, and which would have immediate benefit as 127 
adjunct therapies. This does not preclude future studies, looking at other antimicrobial strategies, 128 
such as, biofilm disruption 5, anti-virulence compounds 13 or efflux pump inhibition 14, but it does 129 
suggest that such studies must be carefully designed to generate useful information. The screening 130 
of existing approved drugs, while attractive from a regulatory standpoint and rapid route to market, 131 
does not directly address challenges of antimicrobial drug development, including the permeability 132 
issue which impacts on drug uptake into Gram-negative bacteria 15, nor the relatively limited 133 
chemical space inhabited by most classical drugs 16.  134 
 135 
  136 
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Table 1: Structures and antimicrobial profiles of interesting hits from the screen. Shaded boxes 215 
illustrate direct or ARB activities, in M, of compounds in combination with meropenem (MEM), 216 
ciprofloxacin (CIP), gentamicin (GEN), tigecycline (TGC) or colistin (CST) in the four Gram-negative 217 
species tested.  Where compounds had activity at both 20 M and 7 M, only 7 M is represented in 218 
the table.219 
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Figure 1: Few ARB hits show any conservation cross-species or with specific antibiotics. Heat map showing ARB hits by species and antibiotic potentiated, 221 
coloured according to the amount of growth inhibition they caused in each species in combination with each antibiotic. (grey is where the combination was 222 
not tested). 223 
 224 
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 225 
Figure 2: Colistin ARB potential of fluspirilene. A wider panel of colistin-resistant strains were tested 226 
in the presence of fluspirilene. Although the K. pneumoniae strain used in the HTCS showed colistin-227 
potentiation by fluspirilene, this was not reflected in a wider panel. However, fluspirilene did 228 
potentiate colistin in other Gram-negative species. Arrows on the K. pneumoniae panel indicate the 229 
change in MIC for two specific strains. This highlights an example where fluspirilene is antagonistic to 230 
colistin but where the MIC is in the same range as some strains where potentiation is observed.    231 
 232 
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